NASDAQ:BDSI - BioDelivery Sciences International Stock Price, Price Target & More

$2.10 0.00 (0.00 %)
(As of 04/26/2018 04:00 PM ET)
Previous Close$2.10
Today's Range$2.05 - $2.15
52-Week Range$1.65 - $3.60
Volume123,351 shs
Average Volume446,591 shs
Market Capitalization$122.74 million
P/E Ratio-5.38
Dividend YieldN/A
Beta0.44

About BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International logoBioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. has a licensing and development agreement with Evonik Corporation and Meda AB. The company was founded in 1997 and is headquartered in Raleigh, North Carolina.

Receive BDSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BDSI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:BDSI
CUSIP09060J10
Phone919-582-9050

Debt

Debt-to-Equity Ratio5.37%
Current Ratio1.52%
Quick Ratio1.29%

Price-To-Earnings

Trailing P/E Ratio-5.38
Forward P/E Ratio-2.73
P/E GrowthN/A

Sales & Book Value

Annual Sales$61.99 million
Price / Sales1.98
Cash FlowN/A
Price / CashN/A
Book Value$0.16 per share
Price / Book13.13

Profitability

EPS (Most Recent Fiscal Year)($0.39)
Net Income$5.28 million
Net Margins8.52%
Return on Equity22.93%
Return on Assets5.54%

Miscellaneous

Employees116
Outstanding Shares58,450,000

How to Become a New Pot Stock Millionaire

BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions

What is BioDelivery Sciences International's stock symbol?

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

How were BioDelivery Sciences International's earnings last quarter?

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) posted its earnings results on Thursday, March, 15th. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.05. The specialty pharmaceutical company earned $12.51 million during the quarter, compared to analysts' expectations of $9.83 million. BioDelivery Sciences International had a net margin of 8.52% and a return on equity of 22.93%. View BioDelivery Sciences International's Earnings History.

When is BioDelivery Sciences International's next earnings date?

BioDelivery Sciences International is scheduled to release their next quarterly earnings announcement on Monday, May, 14th 2018. View Earnings Estimates for BioDelivery Sciences International.

What price target have analysts set for BDSI?

7 equities research analysts have issued 1 year price targets for BioDelivery Sciences International's shares. Their predictions range from $4.00 to $5.00. On average, they anticipate BioDelivery Sciences International's stock price to reach $4.4286 in the next twelve months. View Analyst Ratings for BioDelivery Sciences International.

What are Wall Street analysts saying about BioDelivery Sciences International stock?

Here are some recent quotes from research analysts about BioDelivery Sciences International stock:
  • 1. Cantor Fitzgerald analysts commented, "Positives from the quarter: 1) BDSI announced it had secured preferred coverage for Belbuca with Humana (HUM, Neutral) effective March 1. Effective Jan. 1, 2018, United Healthcare (UNH, OW) removed step edits for Belbuca, and CVS/Caremark (CVS, Not covered) and ProCareRx moved Belbuca to a preferred position. Additionally, Belbuca and Butrans have been added to the Ohio Workers Comp formulary as preferred medications, effective 4/1/18; 2) Belbuca prescriptions grew 10% in 4Q17 vs. 3Q17, and have continued to grow in 2018; 3) Scott Plesha was appointed to the role of President; and 4) cash and equivalents totaled $21.9MM at 12/31/17, which should fund operations into 2H18. Management noted on the call that it could potentially qualify for an additional tranche of its loan agreement in 2018. Other levers the company has to decrease cash burn and extend the cash runway include better-than- expected sales, lower R&D and SG&A spending, and potential partnerships or divestments of the company’s other products." (3/15/2018)
  • 2. According to Zacks Investment Research, "BioDelivery has secured improved positioning in six new managed care contracts providing preferred access to its key drug, Bunavail, since July 2016. This is expected to boost the drug’s sales and profitability in turn. Meanwhile, its second marketed drug, Belbuca, recently received an approval in Canada for severe pain that should support further sales growth. BioDelivery’s shares have significantly outperformed the industry in the last one year. However, the company suffered a setback with the discontinuation of clonidine topical gel for management of painful diabetic neuropathy in December 2016. BioDelivery’s portfolio as well as its pipeline candidates may also face a severe competition as it targets a highly genericized and crowded market." (2/14/2018)

Who are some of BioDelivery Sciences International's key competitors?

Who are BioDelivery Sciences International's key executives?

BioDelivery Sciences International's management team includes the folowing people:
  • Dr. Francis E. O'Donnell Jr., M.D., Exec. Chairman (Age 68)
  • Dr. Mark A. Sirgo, Vice Chairman & Interim CEO (Age 64)
  • Mr. Ernest Robert De Paolantonio CPA, MBA, CFO, Corp. Sec. & Treasurer (Age 65)
  • Dr. Niraj Vasisht, CTO & Sr. VP of Product Devel. (Age 54)
  • Mr. Scott M. Plesha, Pres

Has BioDelivery Sciences International been receiving favorable news coverage?

News headlines about BDSI stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BioDelivery Sciences International earned a media sentiment score of 0.10 on Accern's scale. They also gave media headlines about the specialty pharmaceutical company an impact score of 46.64 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are BioDelivery Sciences International's major shareholders?

BioDelivery Sciences International's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BROADFIN CAPITAL, LLC (7.30%). Company insiders that own BioDelivery Sciences International stock include Barry I Feinberg, Francis E Odonnell Jr, Mark A Sirgo, Niraj Vasisht, Paolantonio Ernest Robert De, Samuel P Sears, Jr and William B Stone. View Institutional Ownership Trends for BioDelivery Sciences International.

How do I buy shares of BioDelivery Sciences International?

Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioDelivery Sciences International's stock price today?

One share of BDSI stock can currently be purchased for approximately $2.10.

How big of a company is BioDelivery Sciences International?

BioDelivery Sciences International has a market capitalization of $122.74 million and generates $61.99 million in revenue each year. The specialty pharmaceutical company earns $5.28 million in net income (profit) each year or ($0.39) on an earnings per share basis. BioDelivery Sciences International employs 116 workers across the globe.

How can I contact BioDelivery Sciences International?

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]


MarketBeat Community Rating for BioDelivery Sciences International (BDSI)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  351 (Vote Outperform)
Underperform Votes:  178 (Vote Underperform)
Total Votes:  529
MarketBeat's community ratings are surveys of what our community members think about BioDelivery Sciences International and other stocks. Vote "Outperform" if you believe BDSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDSI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BioDelivery Sciences International (NASDAQ:BDSI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for BioDelivery Sciences International in the last 12 months. Their average twelve-month price target is $4.4286, suggesting that the stock has a possible upside of 110.88%. The high price target for BDSI is $5.00 and the low price target for BDSI is $4.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.862.862.83
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.4286$4.4286$4.5714$4.50
Price Target Upside: 110.88% upside123.67% upside79.27% upside52.54% upside

BioDelivery Sciences International (NASDAQ:BDSI) Consensus Price Target History

Price Target History for BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International (NASDAQ:BDSI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2018HC WainwrightSet Price TargetBuy$4.00LowView Rating Details
3/15/2018Cantor FitzgeraldReiterated RatingBuy$5.00HighView Rating Details
1/26/2018Seaport Global SecuritiesInitiated CoverageBuy -> Buy$5.00HighView Rating Details
11/13/2017Roth CapitalSet Price TargetBuy$5.00N/AView Rating Details
10/22/2017Piper JaffraySet Price TargetBuy$4.00N/AView Rating Details
7/24/2017Janney Montgomery ScottBoost Price TargetBuy -> Fair Value$3.00 -> $4.00HighView Rating Details
5/16/2017FBR & CoSet Price TargetBuy$4.00MediumView Rating Details
(Data available from 4/26/2016 forward)

Earnings

BioDelivery Sciences International (NASDAQ:BDSI) Earnings History and Estimates Chart

Earnings by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International (NASDAQ:BDSI) Earnings Estimates

2018 EPS Consensus Estimate: ($0.78)
2019 EPS Consensus Estimate: ($0.13)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.23)($0.21)($0.22)
Q2 20182($0.21)($0.20)($0.21)
Q3 20182($0.19)($0.18)($0.19)
Q4 20182($0.18)($0.16)($0.17)
Q1 20191($0.10)($0.10)($0.10)
Q2 20191($0.06)($0.06)($0.06)
Q3 20191($0.01)($0.01)($0.01)
Q4 20191$0.04$0.04$0.04

BioDelivery Sciences International (NASDAQ BDSI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/2018($0.22)N/AView Earnings Details
3/15/2018Q4 2017($0.24)($0.29)$9.83 million$12.51 millionViewListenView Earnings Details
11/9/2017Q3 2017($0.22)($0.21)$9.40 million$11.25 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.23)($0.27)$8.45 million$8.70 millionViewListenView Earnings Details
5/15/2017Q1 2017$0.09$0.58$27.07 million$29.48 millionViewN/AView Earnings Details
3/17/2017Q4 2016($0.26)($0.2890)$6.37 million$3.90 millionViewN/AView Earnings Details
11/9/2016Q316($0.26)($0.30)$3.58 million$3.60 millionViewListenView Earnings Details
8/9/2016Q216($0.31)($0.31)$3.35 million$5.00 millionViewN/AView Earnings Details
5/10/2016Q116($0.35)($0.36)$2.96 million$3.00 millionViewListenView Earnings Details
3/10/2016Q415$0.55$0.19$52.40 million$32.20 millionViewListenView Earnings Details
11/9/2015Q315($0.34)($0.39)$1.56 million$1.20 millionViewN/AView Earnings Details
8/10/2015Q215($0.31)($0.37)$3.29 million$1.70 millionViewListenView Earnings Details
5/11/2015Q115($0.20)($0.16)$10.80 million$13.10 millionViewListenView Earnings Details
3/16/2015Q414($0.40)($0.51)$4.00 million$2.50 millionViewN/AView Earnings Details
11/5/2014Q3 2014($0.29)($0.39)$3.02 million$1.82 millionViewN/AView Earnings Details
8/7/2014Q2 2014($0.07)($0.14)$11.65 million$13.89 millionViewN/AView Earnings Details
5/9/2014Q114($0.15)($0.11)$11.60 million$20.69 millionViewN/AView Earnings Details
3/14/2014($0.22)($0.33)$4.88 million$3.97 millionViewN/AView Earnings Details
11/12/2013Q3 2013($0.32)($0.49)$2.68 million$3.00 millionViewN/AView Earnings Details
8/9/2013Q2 2013($0.34)($0.35)$1.79 million$2.76 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.42)($0.36)$1.36 million$1.62 millionViewN/AView Earnings Details
3/18/2013Q4 2012($0.18)$0.09ViewN/AView Earnings Details
11/8/2012Q3 2012($0.32)($0.64)ViewN/AView Earnings Details
8/9/2012Q2 2012$0.27$0.08ViewN/AView Earnings Details
5/10/2012Q1 2012$0.64$0.75ViewN/AView Earnings Details
3/19/2012Q4 2011($0.21)($0.16)ViewN/AView Earnings Details
11/14/2011Q3 2011($0.21)($0.17)ViewN/AView Earnings Details
5/13/2011Q1 2011($0.25)($0.34)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

BioDelivery Sciences International (NASDAQ:BDSI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

BioDelivery Sciences International (NASDAQ BDSI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.00%
Institutional Ownership Percentage: 44.16%
Insider Trading History for BioDelivery Sciences International (NASDAQ:BDSI)
Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International (NASDAQ BDSI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/10/2018Mark A SirgoDirectorSell100,000$2.06$206,000.002,585,966View SEC Filing  
4/6/2018Paolantonio Ernest Robert DeCFOSell64,155$2.09$134,083.9597,731View SEC Filing  
3/8/2018Francis E Odonnell JrDirectorSell113,876$2.14$243,694.64319,717View SEC Filing  
1/19/2018Mark A SirgoDirectorSell709,502$2.73$1,936,940.461,759,262View SEC Filing  
1/17/2018Mark A SirgoDirectorSell108,000$2.57$277,560.001,759,262View SEC Filing  
1/3/2018Mark A SirgoDirectorSell162,509$2.78$451,775.021,759,262View SEC Filing  
9/21/2017Mark A SirgoInsiderSell201,373$2.84$571,899.321,509,262View SEC Filing  
9/20/2017Mark A SirgoCEOSell65,405$2.75$179,863.751,509,262View SEC Filing  
9/19/2017Mark A SirgoCEOSell24,516$2.75$67,419.001,509,262View SEC Filing  
9/18/2017Mark A SirgoCEOSell6,000$2.85$17,100.001,509,262View SEC Filing  
9/15/2017Mark A SirgoCEOSell54,833$2.90$159,015.701,509,262View SEC Filing  
9/14/2017Mark A SirgoCEOSell50,000$2.95$147,500.001,509,262View SEC Filing  
3/31/2017Mark A SirgoCEOSell110,895$1.90$210,700.501,670,157View SEC Filing  
3/23/2017Francis E Odonnell JrDirectorSell750$1.90$1,425.00272,049View SEC Filing  
3/23/2017Niraj VasishtSVPSell530$1.90$1,007.00272,943View SEC Filing  
3/23/2017Paolantonio Ernest Robert DeCFOSell170$1.90$323.0096,634View SEC Filing  
1/30/2017Niraj VasishtInsiderSell6,905$1.91$13,188.55178,727View SEC Filing  
12/1/2016Samuel P. Sears, Jr.DirectorSell12,000$1.67$20,040.00View SEC Filing  
11/23/2016Barry I FeinbergDirectorBuy2,000$1.67$3,340.00View SEC Filing  
11/17/2016Barry I FeinbergDirectorBuy3,000$1.87$5,610.00View SEC Filing  
9/23/2016Francis E Odonnell JrDirectorSell100,000$2.57$257,000.00View SEC Filing  
9/23/2016Niraj VasishtInsiderSell47,000$2.43$114,210.0073,081View SEC Filing  
9/22/2016Paolantonio Ernest Robert DeCFOSell14,800$2.44$36,112.0014,866View SEC Filing  
8/25/2016Barry I FeinbergDirectorBuy2,500$2.55$6,375.00View SEC Filing  
8/11/2016William B StoneDirectorSell16,000$2.57$41,120.00122,675View SEC Filing  
3/21/2016Charles BramlageDirectorBuy8,850$2.82$24,957.0028,150View SEC Filing  
3/18/2016Barry I FeinbergDirectorBuy10,000$2.74$27,400.00View SEC Filing  
3/18/2016Niraj VasishtCTOBuy1,000$2.80$2,800.0068,420View SEC Filing  
3/17/2016Paolantonio Ernest Robert DeCFOBuy4,000$2.60$10,400.0013,383View SEC Filing  
11/24/2015Francis E Odonnell JrDirectorSell50,000$6.01$300,500.00View SEC Filing  
11/13/2015Thomas D'alonzoDirectorBuy4,528$5.52$24,994.5676,379View SEC Filing  
9/3/2015Francis E Odonnell JrDirectorSell20,000$6.43$128,600.00144,671View SEC Filing  
8/26/2015Paolantonio Ernest Robert DeCFOBuy1,650$6.20$10,230.009,383View SEC Filing  
8/13/2015William B StoneDirectorSell11,500$7.01$80,615.00View SEC Filing  
6/16/2015Francis E Odonnell JrDirectorSell21,597$8.03$173,423.91View SEC Filing  
6/16/2015Mark A SirgoCEOSell4,187$7.97$33,370.39View SEC Filing  
5/26/2015Barry I FeinbergDirectorBuy2,000$7.84$15,680.00View SEC Filing  
5/14/2015Barry I FeinbergDirectorBuy2,000$8.54$17,080.00View SEC Filing  
5/13/2015Thomas D'alonzoDirectorBuy6,226$8.07$50,243.82View SEC Filing  
12/26/2014Francis E Odonnell JrDirectorSell70,000$12.00$840,000.00View SEC Filing  
12/15/2014Mark A SirgoCEOBuy2,500$12.23$30,575.00View SEC Filing  
12/10/2014Samuel P Sears JrDirectorSell7,853$15.03$118,030.59View SEC Filing  
11/12/2014William B StoneDirectorSell14,000$16.11$225,540.00View SEC Filing  
9/4/2014Barry I FeinbergDirectorBuy1,000$15.18$15,180.00View SEC Filing  
9/4/2014Mark A SirgoCEOBuy2,000$15.04$30,080.00View SEC Filing  
8/27/2014Andrew L FinnEVPSell90,000$15.00$1,350,000.00View SEC Filing  
8/22/2014Charles BramlageDirectorBuy1,800$13.85$24,930.00View SEC Filing  
6/25/2014Paolantonio Ernest Robert DeCFOBuy1,250$12.13$15,162.50View SEC Filing  
6/12/2014Samuel P Sears JrDirectorSell5,000$12.33$61,650.00View SEC Filing  
6/11/2014Francis E Odonnell JrDirectorSell125,000$11.04$1,380,000.00View SEC Filing  
3/26/2014Francis Odonnell, Jr.DirectorSell50,000$8.04$402,000.00View SEC Filing  
3/20/2014Samuel Sears, Jr.DirectorSell4,000$9.00$36,000.0019,853View SEC Filing  
3/11/2014Andrew FinnEVPSell80,000$9.99$799,200.00660,450View SEC Filing  
3/11/2014William StoneDirectorSell35,000$10.00$350,000.0063,178View SEC Filing  
2/20/2014Andrew FinnEVPSell18,737$8.84$165,635.08740,450View SEC Filing  
2/20/2014Francis Odonnell, Jr.DirectorSell70,000$8.92$624,400.002,521,751View SEC Filing  
2/20/2014Mark SirgoCEOSell42,000$8.92$374,640.00913,250View SEC Filing  
1/24/2014Andrew FinnEVPSell143,679$9.03$1,297,421.37705,653View SEC Filing  
1/24/2014James McnultySVPSell89,223$8.73$778,916.7949,399View SEC Filing  
1/24/2014John SheaDirectorSell130,000$8.78$1,141,400.0013,305View SEC Filing  
1/24/2014Mark SirgoCEOSell116,253$9.01$1,047,439.53815,250View SEC Filing  
11/18/2013Mark SirgoCEOBuy2,337$4.29$10,025.73874,179View SEC Filing  
9/19/2013Francis Odonnell, Jr.DirectorSell95,000$5.36$509,200.003,121,751View SEC Filing  
9/11/2013Samuel P Sears JrDirectorSell2,000$5.37$10,740.00View SEC Filing  
9/9/2013Samuel P Sears JrDirectorSell7,500$5.05$37,875.00View SEC Filing  
8/26/2013Andrew FinnEVPBuy5,000$4.58$22,900.00775,653View SEC Filing  
8/16/2013Mark SirgoCEOBuy5,100$4.43$22,593.00871,842View SEC Filing  
8/15/2013William StoneDirectorSell6,825$4.44$30,303.0063,175View SEC Filing  
8/14/2013James McnultyCFOBuy5,000$4.50$22,500.0049,399View SEC Filing  
6/21/2013Mark A SirgoCEOBuy3,400$4.30$14,620.00View SEC Filing  
6/20/2013Francis E Odonnell JrDirectorSell72,689$4.36$316,924.04View SEC Filing  
6/5/2013Samuel P Sears JrDirectorSell5,000$4.42$22,100.00View SEC Filing  
12/21/2012Andrew L FinnEVPBuy3,000$3.85$11,550.00View SEC Filing  
12/21/2012Mark A SirgoCEOBuy4,975$4.02$19,999.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BioDelivery Sciences International (NASDAQ BDSI) News Headlines

Source:
DateHeadline
BioDelivery Sciences International, Inc. (BDSI) Expected to Announce Quarterly Sales of $10.77 MillionBioDelivery Sciences International, Inc. (BDSI) Expected to Announce Quarterly Sales of $10.77 Million
www.americanbankingnews.com - April 21 at 2:52 AM
 Brokerages Expect BioDelivery Sciences International, Inc. (BDSI) to Post -$0.23 Earnings Per Share Brokerages Expect BioDelivery Sciences International, Inc. (BDSI) to Post -$0.23 Earnings Per Share
www.americanbankingnews.com - April 19 at 3:10 PM
Recent Analysis Shows J.Jill, BankUnited, Toronto Dominion Bank, Adamis Pharmaceuticals, BioDelivery Sciences International, and First Solar Market Influences — Renewed Outlook, Key Drivers of GrowthRecent Analysis Shows J.Jill, BankUnited, Toronto Dominion Bank, Adamis Pharmaceuticals, BioDelivery Sciences International, and First Solar Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - April 19 at 9:30 AM
BioDelivery Sciences International (BDSI) Upgraded by Zacks Investment Research to BuyBioDelivery Sciences International (BDSI) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - April 18 at 7:30 PM
Q1 2018 Earnings Estimate for BioDelivery Sciences International, Inc. (BDSI) Issued By William BlairQ1 2018 Earnings Estimate for BioDelivery Sciences International, Inc. (BDSI) Issued By William Blair
www.americanbankingnews.com - April 18 at 7:58 AM
Why Is BioDelivery Sciences (BDSI) Up 2.4% Since Its Last Earnings Report?Why Is BioDelivery Sciences (BDSI) Up 2.4% Since Its Last Earnings Report?
finance.yahoo.com - April 16 at 9:34 AM
BioDelivery Sciences International, Inc. (BDSI) Director Mark A. Sirgo Sells 100,000 SharesBioDelivery Sciences International, Inc. (BDSI) Director Mark A. Sirgo Sells 100,000 Shares
www.americanbankingnews.com - April 13 at 10:10 PM
BioDelivery Sciences International (BDSI) PT Set at $4.00 by HC WainwrightBioDelivery Sciences International (BDSI) PT Set at $4.00 by HC Wainwright
www.americanbankingnews.com - April 13 at 2:17 PM
BioDelivery Sciences International (BDSI) Given a $5.00 Price Target by HC Wainwright AnalystsBioDelivery Sciences International (BDSI) Given a $5.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 10 at 11:38 PM
BRIEF-Broadfin Capital Reports 7.3 Pct Stake In Biodelivery SciencesBRIEF-Broadfin Capital Reports 7.3 Pct Stake In Biodelivery Sciences
www.reuters.com - April 10 at 9:28 AM
BioDelivery Sciences International, Inc. (BDSI) Receives Average Recommendation of "Buy" from BrokeragesBioDelivery Sciences International, Inc. (BDSI) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 8 at 7:33 AM
Paolantonio Ernest Robert De Sells 64,155 Shares of BioDelivery Sciences International, Inc. (BDSI) StockPaolantonio Ernest Robert De Sells 64,155 Shares of BioDelivery Sciences International, Inc. (BDSI) Stock
www.americanbankingnews.com - April 6 at 7:33 PM
 Analysts Expect BioDelivery Sciences International, Inc. (BDSI) Will Post Quarterly Sales of $11.04 Million Analysts Expect BioDelivery Sciences International, Inc. (BDSI) Will Post Quarterly Sales of $11.04 Million
www.americanbankingnews.com - April 4 at 2:32 AM
From BDSI to Red Hat: The Triangles top inside stock sales of 1Q2018From BDSI to Red Hat: The Triangle's top inside stock sales of 1Q2018
www.bizjournals.com - April 3 at 9:11 AM
BioDelivery Sciences International, Inc. (BDSI) Expected to Announce Earnings of -$0.23 Per ShareBioDelivery Sciences International, Inc. (BDSI) Expected to Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - April 2 at 5:16 PM
BioDelivery Sciences International, Inc. to Post Q1 2018 Earnings of ($0.23) Per Share, Seaport Global Securities Forecasts (BDSI)BioDelivery Sciences International, Inc. to Post Q1 2018 Earnings of ($0.23) Per Share, Seaport Global Securities Forecasts (BDSI)
www.americanbankingnews.com - March 26 at 1:06 AM
BioDelivery Sciences International, Inc. to Post FY2018 Earnings of ($0.70) Per Share, Cantor Fitzgerald Forecasts (BDSI)BioDelivery Sciences International, Inc. to Post FY2018 Earnings of ($0.70) Per Share, Cantor Fitzgerald Forecasts (BDSI)
www.americanbankingnews.com - March 23 at 10:56 AM
BioDelivery Sciences (BDSI) in Focus: Stock Moves 5.1% Higher - NasdaqBioDelivery Sciences (BDSI) in Focus: Stock Moves 5.1% Higher - Nasdaq
www.nasdaq.com - March 21 at 4:59 PM
Blog Exposure - Dova Pharma Inked Agreement with Fosun Pharma for Distribution of Avatrombopag in Mainland China and Hong KongBlog Exposure - Dova Pharma Inked Agreement with Fosun Pharma for Distribution of Avatrombopag in Mainland China and Hong Kong
finance.yahoo.com - March 21 at 9:45 AM
BioDelivery Sciences (BDSI) in Focus: Stock Moves 5.1% HigherBioDelivery Sciences (BDSI) in Focus: Stock Moves 5.1% Higher
finance.yahoo.com - March 21 at 9:45 AM
BioDelivery Sciences International (BDSI) Given a $4.00 Price Target by HC Wainwright AnalystsBioDelivery Sciences International (BDSI) Given a $4.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 19 at 5:02 PM
William Blair Comments on BioDelivery Sciences International, Inc.s Q1 2019 Earnings (BDSI)William Blair Comments on BioDelivery Sciences International, Inc.'s Q1 2019 Earnings (BDSI)
www.americanbankingnews.com - March 19 at 6:46 AM
BioDelivery Sciences International, Inc. (BDSI) Expected to Post Quarterly Sales of $9.50 MillionBioDelivery Sciences International, Inc. (BDSI) Expected to Post Quarterly Sales of $9.50 Million
www.americanbankingnews.com - March 18 at 4:07 AM
BioDelivery (BDSI) Q4 Loss Wider-Than-Expected, Sales Up Y/Y - NasdaqBioDelivery (BDSI) Q4 Loss Wider-Than-Expected, Sales Up Y/Y - Nasdaq
www.nasdaq.com - March 17 at 10:11 AM
BioDelivery (BDSI) Q4 Loss Wider-Than-Expected, Sales Up Y/YBioDelivery (BDSI) Q4 Loss Wider-Than-Expected, Sales Up Y/Y
finance.yahoo.com - March 16 at 4:53 PM
 Brokerages Anticipate BioDelivery Sciences International, Inc. (BDSI) to Announce -$0.25 EPS Brokerages Anticipate BioDelivery Sciences International, Inc. (BDSI) to Announce -$0.25 EPS
www.americanbankingnews.com - March 16 at 3:21 PM
BioDelivery Sciences Internationals (BDSI) CEO Mark Sirgo on Q4 2017 Results - Earnings Call TranscriptBioDelivery Sciences International's (BDSI) CEO Mark Sirgo on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - March 16 at 10:02 AM
CORRECTING and REPLACING -- BioDelivery Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate UpdateCORRECTING and REPLACING -- BioDelivery Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 16 at 10:02 AM
Edited Transcript of BDSI earnings conference call or presentation 15-Mar-18 8:30pm GMTEdited Transcript of BDSI earnings conference call or presentation 15-Mar-18 8:30pm GMT
finance.yahoo.com - March 16 at 10:02 AM
Raleigh pharma quadruples revenue, lands new contractRaleigh pharma quadruples revenue, lands new contract
finance.yahoo.com - March 16 at 10:02 AM
BioDelivery Sciences International (BDSI) Announces Quarterly  Earnings ResultsBioDelivery Sciences International (BDSI) Announces Quarterly Earnings Results
www.americanbankingnews.com - March 16 at 8:52 AM
BioDelivery Sciences Internationals (BDSI) "Buy" Rating Reiterated at Cantor FitzgeraldBioDelivery Sciences International's (BDSI) "Buy" Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - March 15 at 9:26 PM
BioDelivery Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate UpdateBioDelivery Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 15 at 4:43 PM
What You Must Know About BioDelivery Sciences International Inc’s (NASDAQ:BDSI) ROEWhat You Must Know About BioDelivery Sciences International Inc’s (NASDAQ:BDSI) ROE
finance.yahoo.com - March 15 at 10:17 AM
BioDelivery Sciences to Present at the Oppenheimer 28th Annual Healthcare Conference - GlobeNewswire (press release)BioDelivery Sciences to Present at the Oppenheimer 28th Annual Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - March 14 at 12:14 PM
BioDelivery Sciences to Present at the Oppenheimer 28th Annual Healthcare ConferenceBioDelivery Sciences to Present at the Oppenheimer 28th Annual Healthcare Conference
finance.yahoo.com - March 14 at 12:14 PM
Francis E. Odonnell, Jr. Sells 113,876 Shares of BioDelivery Sciences International, Inc. (BDSI) StockFrancis E. Odonnell, Jr. Sells 113,876 Shares of BioDelivery Sciences International, Inc. (BDSI) Stock
www.americanbankingnews.com - March 9 at 6:32 PM
BioDelivery Sciences International (BDSI) Scheduled to Post Quarterly Earnings on ThursdayBioDelivery Sciences International (BDSI) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - March 8 at 1:11 AM
BioDelivery Sciences to Host Conference Call and Webcast Reporting Fourth Quarter and Full-Year 2017 Financial Results on Thursday, March 15BioDelivery Sciences to Host Conference Call and Webcast Reporting Fourth Quarter and Full-Year 2017 Financial Results on Thursday, March 15
finance.yahoo.com - March 7 at 9:48 AM
BioDelivery Sciences International, Inc. (BDSI) Shares Sold by Stonepine Capital Management LLCBioDelivery Sciences International, Inc. (BDSI) Shares Sold by Stonepine Capital Management LLC
www.americanbankingnews.com - March 6 at 2:53 PM
BioDelivery Sciences to Present at the 30th Annual ROTH ConferenceBioDelivery Sciences to Present at the 30th Annual ROTH Conference
finance.yahoo.com - March 5 at 10:04 AM
BioDelivery Sciences International (BDSI) Cut to "Strong Sell" at ValuEngineBioDelivery Sciences International (BDSI) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - March 4 at 11:06 PM
Short Interest in BioDelivery Sciences International, Inc. (BDSI) Rises By 44.8%Short Interest in BioDelivery Sciences International, Inc. (BDSI) Rises By 44.8%
www.americanbankingnews.com - March 3 at 3:26 AM
Broadfin Capital LLC Buys 223,253 Shares of BioDelivery Sciences International, Inc. (BDSI)Broadfin Capital LLC Buys 223,253 Shares of BioDelivery Sciences International, Inc. (BDSI)
www.americanbankingnews.com - March 2 at 5:08 AM
Whats in the Cards for BioDelivery (BDSI) in Q4 Earnings?What's in the Cards for BioDelivery (BDSI) in Q4 Earnings?
www.msn.com - March 1 at 9:24 AM
What's in the Cards for BioDelivery (BDSI) in Q4 Earnings?What's in the Cards for BioDelivery (BDSI) in Q4 Earnings?
finance.yahoo.com - March 1 at 9:24 AM
Royce & Associates LP Grows Holdings in BioDelivery Sciences International, Inc. (BDSI)Royce & Associates LP Grows Holdings in BioDelivery Sciences International, Inc. (BDSI)
www.americanbankingnews.com - March 1 at 8:24 AM
 Brokerages Anticipate BioDelivery Sciences International, Inc. (BDSI) Will Post Quarterly Sales of $9.83 Million Brokerages Anticipate BioDelivery Sciences International, Inc. (BDSI) Will Post Quarterly Sales of $9.83 Million
www.americanbankingnews.com - March 1 at 4:34 AM
Zacks: Brokerages Expect BioDelivery Sciences International, Inc. (BDSI) to Post -$0.25 EPSZacks: Brokerages Expect BioDelivery Sciences International, Inc. (BDSI) to Post -$0.25 EPS
www.americanbankingnews.com - February 27 at 1:24 PM
BioDelivery Sciences International, Inc. (BDSI) Given Consensus Recommendation of "Buy" by BrokeragesBioDelivery Sciences International, Inc. (BDSI) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 17 at 8:46 AM

SEC Filings

BioDelivery Sciences International (NASDAQ:BDSI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BioDelivery Sciences International (NASDAQ:BDSI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BioDelivery Sciences International (NASDAQ BDSI) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.